ClinicalTrials.gg
CompletedNCT02242240Updated Sep 17, 2014

Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Formoterol twice daily and Formoterol once daily in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-09-17.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Boehringer Ingelheim.

Enrollment
109th of 155
95 · median 166
Started
2001
with 11 others
Phase 2
33 of 236
none open now
Registered
179th of 236
by date

Among the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, this one is the 109th largest by enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2001, is one of 33 in phase 2, and was the 179th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Study to establish the lung function effects of added formoterol (12μg QD and BID) during 2-week periods to pharmacodynamic steady state of tiotropium(18μg QD)

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients must sign an consistent with international conference of harmonization (ICH)-good clinical practice (GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions
  • All patients must have a diagnosis of and must meet the following spirometric criteria:

    • Patients must have relatively stable* moderate to severe airway obstruction with an ≤ 60% of predicted normal and FEV1 ≤ 70% of FVC (Visit 1)

      * Patients who have frequent exacerbations (at least three in the preceding year) which could be expected to interfere with the patient's ability to participate in the trial should be excluded. The enrollment of patients who have had an exacerbation within the six-week period prior to planned study entry should be postponed for at least six weeks

    • Predicted normal values will be calculated according to european community for coal and steel (ECCS):
    • Males: FEV1 predicted (L) = 4.30 x Height (metres) - 0.029 x Age (years) - 2.49
    • Females: FEV1 predicted (L) = 3.95 x Height (metres) - 0.025 x Age (years) - 2.60
  • Male or female patients 40 years of age or older
  • Patients must be current or ex-smokers with a smoking history of more than 10 pack-years

    • patients who have never smoked cigarettes must be excluded
  • Patients must be able to perform technically acceptable pulmonary function tests and must be able to maintain records (Patient Daily Record) during the study period as required in the protocol
  • Patients must be able to inhale medication from inhalation capsule delivery systems (the HandiHaler® for the tiotropium and placebo capsules and the Aerolizer® for the formoterol capsule) and from a metered dose inhaler

Exclusion criteria

Exclusion Criteria:

  • Patients with significant diseases other than will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
  • Patients with abnormal baseline hematology, blood chemistry, or urinalysis if the abnormality defines a disease listed as an exclusion criterion
  • All patients with a serum glutamate oxaloacetate transaminase () > 80 IU/L, serum glutamate pyruvate transaminase (SGPT) > 80 IU/L, > 17 µmol/L or creatinine > 110 µmol/L (males) / 95 µmol/L (females) will be excluded regardless of clinical condition. Repeat laboratory evaluation will not be conducted in these patients
  • Patients with a recent history (i.e., six months or less) of myocardial infarction
  • Patients with any cardiac arrhythmia requiring drug therapy or who have been hospitalized for heart failure within the past three years
  • Patients with known active tuberculosis
  • Patients on oxygen therapy
  • Patients with history of cystic fibrosis, bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease
  • Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion 1
  • Patients with any respiratory infection in the six weeks prior to the Screening Visit (Visit 1) or during the baseline period
  • Patients with known to anticholinergic drugs, beta adrenergics, lactose or any other components of the inhalation capsule delivery system
  • Patients with a history of cancer within the last three years. Patients with treated basal cell carcinoma are allowed. Patients with successfully treated cancers greater than five years prior to entry will be allowed
  • Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction
  • Patients with known narrow-angle glaucoma
  • Patients using cromolyn sodium or nedocromil sodium
  • Patients using treated with antihistamines (H1 receptor antagonists)
  • Patients using treated with theophyllines
  • Patients on ß-blocker therapy
  • Patients using oral medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day
  • Pregnant or nursing women or women of not using a medically approved means of for the previous 3 months (i.e. oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g., Norplant®)
  • Patients with a history of asthma, allergic rhinitis or atopy or who have a total blood eosinophil count ≥ 600 mm3. A repeat eosinophil count will not be conducted in these patients
  • Patients with significant alcohol or drug abuse within the past two years
  • Patients who have taken an drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)
  • Patients who are currently in a pulmonary rehabilitation program or who have completed a program in the six weeks prior to screening (Visit 1)
  • Patients who currently participating in another study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Tiotropium with single dose of formoterol

    Drug: Formoterol once daily · Drug: Tiotropium once daily

  • Experimental
    Tiotropium with double dose of formoterol

    Drug: Formoterol twice daily · Drug: Tiotropium once daily

  • Experimental
    Tiotropium with Placebo

    Drug: Tiotropium once daily · Drug: Placebo

Interventions

  • DrugFormoterol twice daily
  • DrugFormoterol once daily
  • DrugTiotropium once daily
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Area under the curve from time point zero to 24 hours (AUC0-24h) for forced expiratory volume in one second (FEV1)

    Time frame: Pre-dose, up to 24 hours after start of treatment

  2. Area under the curve from 12 to 24 hours (AUC12-24h) for forced expiratory volume in one second (FEV1)

    Time frame: 12 to 24 hours after start of treatment

Secondary outcomes

  1. Trough FEV1 response on each pulmonary function test day

    Time frame: 24 hours after intake of the last morning dose

  2. Trough forced vital capacity (FVC) response on each pulmonary function test day

    Time frame: Up to 24 hours after start of treatment

  3. FEV1 AUC0-12h on each pulmonary function test day

    Time frame: Up to 12 hours after start of treatment

  4. Individual FEV1measurements at each time point

    Time frame: up to day 58 day after start of treatment

  5. Individual FVC measurements at each time point

    Time frame: up to day 58 day after start of treatment

  6. Individual inspiratory capacity (IC) measurements at each time point

    Time frame: up to day 58 day after start of treatment

  7. Peak expiratory flow rate (PEFR) measured by the patients at home twice daily

    Time frame: up to day 79 after start of treatment

  8. Amount of salbutamol therapy used during the treatment period

    Time frame: up to day 79 after start of treatment

  9. Number of patients with adverse events

    Time frame: Up to 93 days

  10. FVC AUC0-12h on each pulmonary function test day

    Time frame: up to day 58 day after start of treatment

  11. Peak FEV1 response on each pulmonary function test day

    Time frame: within 3 hours after treatment

  12. Peak FVC response on each pulmonary function test day

    Time frame: within 3 hours after treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2001 and a primary completion of Dec 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2014
First posted
Sep 17, 2014
Start
Mar 2001
Primary completionActual
Dec 2001
Last update
Sep 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02242240
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Mar 2001
Primary completion
Dec 2001
Last update
Sep 17, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion